Purchase this article with an account.
Marcel Dominguez, Eric Fourmaux, Laurence Rosier, Laurent Velasque; RAVE2 Study : Two years treatment follow up with intravitreal ranibizumab (Lucentis®) and verteporfin PDTRF combination therapy at month 2 for neovascular age-related macular degeneration (AMD). Invest. Ophthalmol. Vis. Sci. 2014;55(13):3961.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The synergistic effect of a protocol based on intravitreal injection of ranibizumab (3 injections plus prn) associated with Verteporfin PDT administered at reduced fluence (300 mW/cm2, 25J/cm2) on the day of the 2nd ranibizumab injection was presented in ARVO 2012. This paper evaluates the maintenance of the visual acuity benefit two years after the beginning of the protocol and the number of ranibizumab injections required during the second year.
Single-center observational follow-up study of 40 patients of any race aged ≥50 years newly diagnosed with subfoveal choroidal neovascularization of any type (≤5400 µm) due to AMD.
Of 40 included patients 27 achieved the study at one year and 23 were followed up for two years. Ages ranged from 60 to 89 years. Primary subfoveal CNV were 18.5% predominantly classic (5), 29.6% minimally classic (8) and 51.9% occult with no classic (14) precisely characterized by ICG and Fluorescein angiography. Mean visual acuity was 66.4 ± 9.6 at baseline, 76.2±8.2 at Month 12 and 70.8 µm±11.8 at Month 24. Mean visual gain was 9.8±11.8 at Month 12 (p=0.0002) and 4.4±14.7 at Month 24 (p=0.1313). 7 patients (25.9%) gained 15 letters or more at 1 year and they were still 6 (22.2%) after two years. Only 4 patients (14.8%) lost more than 15 letters at 1 year and 2 others (7.2%) during the next year. Mean Ranibizumab injections was 4.0 ± 1.3 for the first year and 0.9 ± 1.3 for second year (total of 4.9±2.1 on 2 years). Mean retreatment injection between Month 3 and Month 12 was 1.0 ± 1.3 and between Month 3 and Month 24 was 1.9±2.1. 13 patients (48%) underwent no additional injection after initial treatment regimen.
These results show the maintenance of a visual acuity benefit two years after the therapeutic association with an average number of only one ranibizumab injection during the second year of follow up.
This PDF is available to Subscribers Only